Researchers have identified specific characteristics that predict whether early-stage melanoma will return after treatment, offering doctors a clearer roadmap for monitoring high-risk patients. A comprehensive study of 1,092 patients with stage IA to IIC melanomas found that 16.3% experienced recurrence, with a median time to recurrence of 2 years, revealing important patterns that could transform how dermatologists approach surveillance and care. Which Melanoma Patients Face the Highest Recurrence Risk? Researchers at the University of California, San Francisco, conducted a retrospective cohort study analyzing melanoma cases diagnosed between 2010 and 2017, with data analyzed from January 1 to March 15, 2025. The study tracked 1,092 patients (median age 60 years; 57% men; 96.7% White) and identified several clinicopathologic variables strongly associated with melanoma returning after initial treatment. The recurrence rates varied dramatically by stage. Among patients with stage IA melanomas, only 4.3% experienced recurrence, but this jumped to 15.1% for stage IB, 28.3% for stage IIA, 37.2% for stage IIB, and 36.4% for stage IIC tumors. The median follow-up period was 7.2 years, providing substantial long-term data on outcomes. What Specific Factors Predict Melanoma Will Return? The study identified seven key characteristics associated with earlier recurrence. These factors help dermatologists determine which patients need more aggressive monitoring and follow-up care: - Tumor Ulceration: Melanomas with ulceration (a breakdown of the skin surface) showed 3.48 times higher risk of recurrence compared to non-ulcerated tumors, representing the strongest predictor identified in the study. - Tumor Thickness: For every additional millimeter of thickness, the risk of recurrence increased by 9%, with the median tumor thickness in the study being 1.1 millimeters and mean thickness 1.9 millimeters. - Scalp or Neck Location: Melanomas on the scalp or neck carried 3.22 times higher recurrence risk compared to those on the arms, making anatomical location a critical prognostic factor. - Face Location: Facial melanomas showed 2.14 times higher recurrence risk compared to arm melanomas, though slightly lower than scalp or neck locations. - Neurotropism: This refers to cancer cells' tendency to grow along nerve fibers, which was associated with 1.96 times higher recurrence risk. - Lymphovascular Invasion: When cancer cells invade blood vessels or lymphatic vessels, recurrence risk increased by 2.52 times. - Presence of Mitoses: The presence of dividing cells within the tumor showed 3.93 times higher recurrence risk, indicating more aggressive tumor behavior. "In this study, for stage IA to IIC melanomas, several clinicopathologic variables (i.e., thickness, ulceration, tumor site, neurotropism, lymphovascular invasion, mitoses) are associated with time to melanoma recurrence," the authors wrote. "Consideration of these factors could help guide surveillance for recurrences". Where Does Melanoma Tend to Return? Understanding where melanoma recurs helps guide monitoring strategies. Among the 178 melanomas that recurred in the study, distant recurrences (cancer spreading to other organs or distant skin sites) were most common at 47.8%, followed by regional recurrences (nearby lymph nodes) at 33.1%, and local recurrences (at the original site) at 19.1%. This pattern suggests that even early-stage melanomas can develop into systemic disease, emphasizing the importance of comprehensive surveillance. How Should Dermatologists Use This Information for Patient Care? - Risk Stratification: Dermatologists can now use these seven factors to categorize patients into risk groups, allowing them to tailor surveillance frequency and intensity based on individual characteristics rather than stage alone. - Personalized Monitoring Schedules: Patients with multiple high-risk factors (such as ulcerated melanomas on the scalp with lymphovascular invasion) may benefit from more frequent clinical examinations and imaging studies compared to those with low-risk features. - Patient Education: Understanding these risk factors allows doctors to have more informed conversations with patients about their specific prognosis and the rationale behind recommended follow-up schedules. - Treatment Decisions: For patients with high-risk features, dermatologists may consider additional interventions such as sentinel lymph node biopsy or adjuvant therapy to reduce recurrence risk. The study was led by Maya Mundada at the University of California, San Francisco, and published online on March 4 in JAMA Dermatology. The research received support from the Department of Defense, the University of California, San Francisco, and the National Center for Advancing Translational Sciences at the National Institutes of Health. While this single-institution study provides valuable insights, researchers noted that missing values in some pathologic variables and the relatively small number of recurrences were limitations. However, the large sample size of 1,092 patients and extended follow-up period of 7.2 years provide robust evidence that these factors should inform clinical decision-making for melanoma surveillance and management. For patients who have been treated for early-stage melanoma, discussing these risk factors with your dermatologist can help establish an appropriate follow-up plan tailored to your individual characteristics and recurrence risk profile.
